Trials / Unknown
UnknownNCT03214913
Controlled Fluid Resuscitation in Sepsis
Controlled Fluid Resuscitation Strategy in Sepsis Patient
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 8 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate two different strategy of fluid resuscitation in sepsis patients
Detailed description
Early goal-directed fluid therapy (EGDT) had been regarded as an important fluid therapy strategy in early sepsis or septic shock patients. In recent years, several randomized control studies showed the EGDT therapy cannot make a better outcome in sepsis patients compared to the standard therapy. A strategy of controlled fluid resuscitation had showed good outcome in critical illness such as severe acute pancreatitis, major trauma. But many aspects of the so-called controlled fluid resuscitation remained controversial. In a previous study on severe acute pancreatitis, we described a bundle of controlled fluid resuscitation which had showed an ideal result with higher survival rate. So, we are going to use the bundle on sepsis patients, and to see if it can bring a better out come in sepsis patients compared to the EGDT strategy. This study aims to determine a better strategy of fluid resuscitation in sepsis patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Early Goal Directed Therapy | EGDT therapy :30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%;If not, use noradrenine,red blood cell transfusion if necessary. |
| OTHER | Ruijin Strategy | Ruijin Strategy:10\~5ml/kg/h,crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary. target: fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-06-30
- First posted
- 2017-07-12
- Last updated
- 2017-07-12
Source: ClinicalTrials.gov record NCT03214913. Inclusion in this directory is not an endorsement.